NCT06353646View on ClinicalTrials.gov

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

NARecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 12, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Pancreatic Cancer
Interventions
BIOLOGICAL

XH001

XH001 will be administered 12 weeks post-tumor resection (+/- 2 weeks)

DRUG

Ipilimumab Injection

Ipilimumab will be administered 12 weeks post-tumor resection (+/- 2 weeks)

DRUG

Sintilimab injection

Sintilimab will be administered 12 weeks post-tumor resection (+/- 2 weeks)

DRUG

Chemotherapy

gemcitabine + capecitabine

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

Sponsors

Collaborators (1)

NeoCura
All Listed Sponsors
collaborator

NeoCura

INDUSTRY

lead

Wu Wenming

OTHER

NCT06353646 - XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer | Biotech Hunter | Biotech Hunter